This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by van Pareren, Y. K. Articles by Hokken-Koelega, A. C. S. Search for Related Content PubMed PubMed Citation Articles by van Pareren, Y. K. Articles by Hokken-Koelega, A. C. S.

Intelligence and Psychosocial Functioning during Long-Term Growth Hormone Therapy in Children Born Small for Gestational Age

Department of Pediatrics, Division of Endocrinology (Y.K.v.P., A.C.S.H.-K.), Sophia Children’s Hospital/Erasmus Medical Centre, 3015 GJ Rotterdam, The Netherlands; and Departments of Pediatric Psychiatry (F.S.M.S., H.M.K.) and Medical Psychology (H.J.D.), Erasmus Medical Centre, 3015 GJ Rotterdam, The Netherlands

Address all correspondence and requests for reprints to: Dr. A. C. S. Hokken-Koelega, M.D., Sophia Children’s Hospital/Erasmus MC, Department of Pediatrics, Division of Endocrinology, Dr. Molewaterplein 60, 3015 GJ Rotterdam, The Netherlands. E-mail: a.hokken{at}erasmusmc.nl.

Short stature is not the only problem faced by small for gestational age (SGA) children. Being born SGA has also been associated with lowered intelligence, poor academic performance, low social competence, and behavioral problems. Although GH treatment in short children born SGA can result in a normalization of height during childhood, the effect of GH treatment on intelligence and psychosocial functioning remains to be investigated. We show the longitudinal results of a randomized, double-blind, GH-dose response study initiated in 1991 to follow growth, intelligence quotient (IQ), and psychosocial functioning in SGA children during long-term GH treatment.

Patients were assigned to one of two treatment groups (1 or 2 mg GH/m² body surface·d, or 0.035 or 0.07 mg/kg·d). Intelligence and psychosocial functioning were evaluated at start of GH treatment (n = 74), after 2 yr of GH treatment (n = 76), and in 2001 (n = 53). IQ was assessed by a short-form Wechsler Intelligence Scale for Children-Revised or Wechsler Adult Intelligence Scale (Block-design and Vocabulary subtests). Behavioral problems were measured by the Achenbach Child Behavior Checklist or Young Adult Behavior Checklist, and self-perception was measured by the Harter Self-Perception Profile.

Mean (SEM) birth length SD score was –3.6 (0.2), mean age and height at start was 7.4 (0.2) yr and –3.0 (0.1) SD score, respectively, mean duration of GH treatment was 8.0 (0.2) yr, and mean age in 2001 was 16.5 (0.3) yr. After 2 yr of GH treatment, 96% of both GH groups showed a height gain SD score of 1 SD from the start of treatment or more, resulting in a normal height (i.e. height –2.0 SD for age and sex) in 70% of the children. In 2001, 48 (91%) of the 53 children participating in this study had reached a normal height. Block-design s-score and the estimated total IQ significantly increased (P < 0.001 and P < 0.001, respectively) from scores significantly lower than Dutch peers at start (P < 0.001 and P < 0.001, respectively) to comparable scores in 2001. The increase over time for the Vocabulary s-score was not significant. Internalizing Behavior SD scores remained comparable to Dutch peers, whereas Externalizing Behavior SD scores and Total Problem Behavior SD scores improved significantly during GH therapy (P < 0.01 and P < 0.05, respectively) to scores comparable to Dutch peers. Self-perception SD scores improved from start of GH treatment until 2001 (P < 0.001) to scores significantly higher than Dutch peers (P < 0.05). No significant differences between the two GH dosage groups were found. Improvement in Externalizing and Total Problem Behavior SD scores over time was significantly related to change in height SD score (P < 0.05 and P < 0.01, respectively), whereas scores over time for Vocabulary, Block-design, Internalizing, or total Harter Self-Perception score were not related to change in height SD scores.

In conclusion, parallel to a GH-induced catch-up growth in adolescents born SGA, IQ, behavior, and self-perception showed a significant improvement over time from scores below average to scores comparable to Dutch peers. In addition, children whose height over time became closer to that of their peers showed less problem behavior.

This article has been cited by other articles:

				R. F. A. de Lind van Wijngaarden, E. P. C. Siemensma, D. A. M. Festen, B. J. Otten, E. G. A. H. van Mil, J. Rotteveel, R. J. H. Odink, G. C. B. Bindels-de Heus, M. van Leeuwen, D. A. J. P. Haring, et al. Efficacy and Safety of Long-Term Continuous Growth Hormone Treatment in Children with Prader-Willi Syndrome J. Clin. Endocrinol. Metab., November 1, 2009; 94(11): 4205 - 4215. [Abstract] [Full Text] [PDF]

				W. A Ester, J. B van Meurs, N. J Arends, A. G Uitterlinden, M. A de Ridder, and A. C Hokken-Koelega The -G1245A IGF1 polymorphism is related with small head size and less brain sparing in small for gestational age born children Eur. J. Endocrinol., April 1, 2009; 160(4): 549 - 555. [Abstract] [Full Text] [PDF]

				E. E. Rogers and R. E. Piecuch Neurodevelopmental Outcomes of Infants Who Experience Intrauterine Growth Restriction NeoReviews, March 1, 2009; 10(3): e100 - e112. [Abstract] [Full Text] [PDF]

				D-M Walker and N Marlow Neurocognitive outcome following fetal growth restriction Arch. Dis. Child. Fetal Neonatal Ed., July 1, 2008; 93(4): F322 - F325. [Abstract] [Full Text] [PDF]

				K. Heinonen, K. Raikkonen, A.-K. Pesonen, E. Kajantie, S. Andersson, J. G. Eriksson, A. Niemela, T. Vartia, J. Peltola, and A. Lano Prenatal and Postnatal Growth and Cognitive Abilities at 56 Months of Age: A Longitudinal Study of Infants Born at Term Pediatrics, May 1, 2008; 121(5): e1325 - e1333. [Abstract] [Full Text] [PDF]

				P. Saenger, P. Czernichow, I. Hughes, and E. O. Reiter Small for Gestational Age: Short Stature and Beyond Endocr. Rev., April 1, 2007; 28(2): 219 - 251. [Abstract] [Full Text] [PDF]

				P. E. Clayton, S. Cianfarani, P. Czernichow, G. Johannsson, R. Rapaport, and A. Rogol Management of the Child Born Small for Gestational Age through to Adulthood: A Consensus Statement of the International Societies of Pediatric Endocrinology and the Growth Hormone Research Society J. Clin. Endocrinol. Metab., March 1, 2007; 92(3): 804 - 810. [Abstract] [Full Text] [PDF]

				K Lagrou, J Vanderfaeillie, C Froidecoeur, M Thomas, G Massa, S Tenoutasse, M Craen, M C Lebrethon, D Beckers, I Francois, et al. Effect of 2 years of high-dose growth hormone therapy on cognitive and psychosocial development in short children born small for gestational age Eur. J. Endocrinol., February 1, 2007; 156(2): 195 - 201. [Abstract] [Full Text] [PDF]

				H Visser-van Balen, G Sinnema, and R Geenen Growing up with idiopathic short stature: psychosocial development and hormone treatment; a critical review. Arch. Dis. Child., May 1, 2006; 91(5): 433 - 439. [Abstract] [Full Text] [PDF]

				D. Gunnell, L. L. Miller, I. Rogers, J. M. P. Holly, and and the ALSPAC Study Team Association of Insulin-like Growth Factor I and Insulin-like Growth Factor-Binding Protein-3 With Intelligence Quotient Among 8- to 9-Year-Old Children in the Avon Longitudinal Study of Parents and Children Pediatrics, November 1, 2005; 116(5): e681 - e686. [Abstract] [Full Text] [PDF]

				C. Gale Commentary: Height and intelligence Int. J. Epidemiol., June 1, 2005; 34(3): 678 - 679. [Full Text] [PDF]

				S. A. Sands Intelligence and Psychosocial Functioning during Long-Term Growth Hormone Therapy in Children Born Small for Gestational Age J. Clin. Endocrinol. Metab., November 1, 2004; 89(11): 5292 - 5294. [Full Text] [PDF]